Skip to main content
SpringerLink
Log in

Diseases of Muscle

  • Chapter
  • First Online:
Clinical Handbook of Neuromuscular Medicine

  • 1114 Accesses

Abstract

Myopathies can present with negative (such as weakness) or positive (such as myalgia and cramps) symptoms. Recognition of certain characteristic patterns of muscle weakness on exam can narrow the differential diagnosis. Serum creatine kinase, focused serologic testing, electromyography, exercise test, muscle imaging, biopsy, and genetic testing are useful to reach a specific diagnosis. The key clinical features, laboratory, EMG, and histopathologic abnormalities of the most common myopathies are discussed below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AQM:

Acute quadriplegic myopathy

CK:

Creatine kinase

DM:

Dermatomyositis

DM1:

Myotonic dystrophy type 1

DM2:

Myotonic dystrophy type 2

FSHD:

Facioscapularhumeral dystrophy

IBM:

Inclusion body myositis

LGMD:

Limb girdle muscular dystrophy

MELAS:

Mitochondrial myopathy, lactic acidosis, and stroke-like episodes

MERRF:

Myoclonic epilepsy and ragged red fibers

MNGIE:

Mitochondrial neurogastro-intestinal encephalomyopathy

OPMD:

Oculopharyngeal muscular dystrophy

PM:

Polymyositis

References

  1. Tarnopolsky M, Stevens M, MacDonald JR, Rodriguez C, Mahoney D, et al. Diagnostic utility of a modified forearm ischemic exercise test and technical issues relevant to exercise testing. Muscle Nerve. 2003;27:359–66.

    Article  PubMed  Google Scholar 

  2. Kazamel M, Sorenson EJ, McEvoy KM, Jones LK, Leep-Hunderfund AN, et al. Clinical spectrum of valosin containing protein (VCP)-opathy. Muscle Nerve. 2016;54:94–9.

    Article  CAS  PubMed  Google Scholar 

  3. Daxinger L, Tapscott SJ, van der Maarel SM. Genetic and epigenetic contributors to FSHD. Curr Opin Genet Dev. 2015;33:56–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Meola G, Jones K, Wei C, Timchenko LT. Dysfunction of protein homeostasis in myotonic dystrophies. Histol Hitopathol. 2013;28:1089–98.

    CAS  Google Scholar 

  5. Smith CA, Gutmann L. Myotonic dystrophy type 1 management and therapeutics. Curr Treat Options Neurol. 2016;18:52.

    Article  PubMed  Google Scholar 

  6. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP. Myotonic dystrophy type 2 is caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864–7.

    Article  CAS  PubMed  Google Scholar 

  7. Liewluck T, Milone M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle Nerve. 2018.

    Google Scholar 

  8. Udd B. Distal myopathies--new genetic entities expand diagnostic challenge. Neuromuscul Disord. 2012;22(1):5–12.

    Article  PubMed  Google Scholar 

  9. Banerjee A, Apponi LH, Pavlath GK, Corbett AH. PABPN1: molecular function and muscle disease. FEBS J. 2013;280:4230–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Engel WK, Askenas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology. 2006;66:S20–9.

    Article  PubMed  Google Scholar 

  11. Ko EH, Rubin AD. Dysphagia due to inclusion body myositis: case presentation and review of the literature. Ann Otol Rhinol Laryngol. 2014;123:605–8.

    Article  PubMed  Google Scholar 

  12. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007;6:620–31.

    Article  PubMed  Google Scholar 

  13. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73:397–407.

    Article  CAS  PubMed  Google Scholar 

  14. Weihl C, Mammen A. Soradic inculsion body myositis – a myodegenerative disease or an inflammatory myopathy. Neuropath Appl Neurobiol. 2017;43:82–91.

    Article  CAS  Google Scholar 

  15. Pinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol. 2016;28:619–24.

    Article  CAS  PubMed  Google Scholar 

  16. Tomaszewski M, Stepien KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011;63:859–66.

    Article  CAS  PubMed  Google Scholar 

  17. Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology. 2008;82:83–8.

    Article  CAS  PubMed  Google Scholar 

  18. Kishnani PS, Corzo D, Leslie ND, Gruskin D, van der Ploeg A, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66:329–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, et al. Survival and long-term outcomes in late-onset Pompe diseae following alglucosidase alpha treatment: a systematic review and meta-analysis. J Neurol. 2017;264:621–30.

    Article  CAS  PubMed  Google Scholar 

  20. Sato S, Ohi T, Nishino I, Sugie H. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve. 2012;45:436–40.

    Article  PubMed  Google Scholar 

  21. Martinuzzi A, Liava A, Trevisi E, Frare M, Tonon C, et al. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle’s disease. Muscle Nerve. 2008;37:350–7.

    Article  CAS  PubMed  Google Scholar 

  22. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. NEJM. 2009;360:838–40.

    Article  CAS  PubMed  Google Scholar 

  23. Lossin C, George AL. Myotonia congenita. Adv Genet. 2008;63:25–55.

    CAS  PubMed  Google Scholar 

  24. Ptacek LJ, George AL, Barchi RL, et al. Mutations in an S4 segment of the adult skeletalmuscle sodium channel cause paramyotonia congenita. Neurology. 1992;8:891–7.

    CAS  Google Scholar 

  25. Statland JM, Fontaine B, Hanna MG, Johnson KE, Kissel JT, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2017.

    Google Scholar 

  26. Nguyen HL, Pieper GH, Wilders R. Andersen-Tawil syndrome: clinical and molecular aspects. Int J Cardiol. 2013;170:1–16.

    Article  PubMed  Google Scholar 

  27. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015;116:4–12.

    Article  CAS  PubMed  Google Scholar 

  28. Fryer RH, Bain JM, De Vivo DC. Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS): a case report and critical reappraisal of treatment options. Pediatr Neurol. 2016;56:59–61.

    Article  PubMed  Google Scholar 

  29. Lara MC, Valentino ML, Torres-Torronteras J, Hirano M, Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci Rep. 2007;27:151–63.

    Article  CAS  PubMed  Google Scholar 

  30. Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology. 1992;42:2082–7.

    Article  CAS  PubMed  Google Scholar 

  31. Rouleau G, Karpati G, Carpenter S, et al. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve. 1987;10:428–38.

    Article  CAS  PubMed  Google Scholar 

  32. Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve. 1997;20:665–73.

    Article  CAS  PubMed  Google Scholar 

  33. Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol. 2008;8:319–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Minnesota, Minneapolis, MN, USA

    Georgios Manousakis MD

Authors
  1. Georgios Manousakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios Manousakis MD .

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA

    David Walk

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Manousakis, G. (2018). Diseases of Muscle. In: Walk, D. (eds) Clinical Handbook of Neuromuscular Medicine . Springer, Cham. https://doi.org/10.1007/978-3-319-67116-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-67116-1_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-67115-4

  • Online ISBN: 978-3-319-67116-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation